Armata Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Deborah Birx

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage	17.8%
CEO tenure	1.3yrs
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Deborah Birx's remuneration changed compared to Armata Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$41m
Jun 30 2024	n/a	n/a	-US$67m
Mar 31 2024	n/a	n/a	-US$80m
Dec 31 2023	US$1m	US$252k	-US$69m

Compensation vs Market: Deborah's total compensation ($USD1.41M) is above average for companies of similar size in the US market ($USD649.07K).

Compensation vs Earnings: Insufficient data to compare Deborah's compensation with company performance.

CEO

Deborah Birx (67 yo)

1.3yrs

Tenure

US$1,411,908

Compensation

Dr. Deborah L. Birx, M.D., serves as CEO & Director of Armata Pharmaceuticals, Inc. since July 11, 2023. She is Member of Palantir Federal Advisory Board at Palantir Technologies Inc. since October 2022. S...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Deborah Birx	CEO & Director	1.3yrs	US$1.41m	no data
David House	Senior VP of Finance & Principal Financial Officer	less than a year	no data	no data
Peter Hubbard	Vice President of Operations	less than a year	no data	no data
Pierre Kyme	Chief Business Officer	less than a year	no data	0.028% $ 22.5k

0.6yrs

Average Tenure

Experienced Management: ARMP's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Deborah Birx	CEO & Director	1.3yrs	US$1.41m	no data
Joseph Patti	Independent Director	5.5yrs	US$86.19k	0% $ 0
Jules Haimovitz	Independent Director	3.6yrs	US$74.88k	0% $ 0
Odysseas Kostas	Independent Director	4.8yrs	US$64.19k	0% $ 0
Athena Papas	Member of C16G2 Clinical Advisory Board	no data	no data	no data
Sarah Schlesinger	Independent Director	4.8yrs	US$66.19k	0% $ 0
Todd Peterson	Independent Director	5.1yrs	US$73.19k	0% $ 0
Robin Kramer	Independent Chairman of the Board	3.9yrs	US$105.50k	0% $ 0
James Bader	Member of C16G2 Clinical Advisory Board	no data	no data	no data
Ann Griffen	Member of C16G2 Clinical Advisory Board	no data	no data	no data
Mark Wolff	Member of C16G2 Clinical Advisory Board	no data	no data	no data
Domenick Zero	Member of C16G2 Clinical Advisory Board	no data	no data	no data

4.8yrs

Average Tenure

64yo

Average Age

Experienced Board: ARMP's board of directors are considered experienced (4.8 years average tenure).

Armata Pharmaceuticals Management

Management criteria checks 1/4

Key information

Recent management updates

Armata Pharmaceuticals Announces Principal Financial Officer Changes

Insufficient new directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

Armata Pharmaceuticals, Inc. Announces CFO Changes

Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Aug 29, 2023

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 32%, EPS upgraded

Armata Pharmaceuticals Announces Principal Financial Officer Changes

Second quarter 2024 earnings released: EPS: US$0.25 (vs US$0.098 loss in 2Q 2023)

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Armata Pharmaceuticals, Inc. Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled Ap-Pa02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas Aeruginosa Infection

Consensus EPS estimates fall by 43%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

New minor risk - Market cap size

Consensus EPS estimates fall by 52%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus

Armata Pharmaceuticals, Inc. Announces CFO Changes

Consensus revenue estimates decrease by 44%, EPS upgraded

New minor risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Aug 29, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Armata Pharmaceuticals, Inc. Announces Executive Changes

Full year 2022 earnings: EPS and revenues miss analyst expectations

Armata Pharmaceuticals, Inc. announced that it has received $30 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals, Inc. announced that it has received $30 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

High number of new directors

Price target increased to US$8.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Armata Pharmaceuticals, Inc., Annual General Meeting, Nov 16, 2022

Price target increased to US$8.00

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus Aureus

Consensus forecasts updated

High number of new directors

Armata Pharmaceuticals, Inc. announced that it has received $45 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals, Inc. Announces CFO Changes

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Armata Pharmaceuticals, Inc. Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis

Price target increased to US$8.00

Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs

Third quarter 2021 earnings released: US$0.22 loss per share (vs US$0.31 loss in 3Q 2020)

Consensus forecasts updated

Price target increased to US$8.00

Consensus revenue estimates fall to US$666.7k

Armata Pharmaceuticals Inc. announced that it has received $20 million in funding from Innoviva, Inc.

Analysts update estimates

New 90-day high: US$5.07

New 90-day low: US$2.83

Earnings beat expectations, revenue disappoints

New 90-day high: US$3.94

Armata Pharmaceuticals Inc. Appoints Mina Pastagia as Vice President of Clinical Development

Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections

New 90-day low - US$3.26

Armata Pharmaceuticals Inc.(AMEX:ARMP) dropped from Russell Microcap Value Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure